ZYUS Life Sciences Reports Preliminary Results from Ongoing Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug

Executive Summary

• ZYUS Life Sciences reported favorable preliminary safety and analgesic efficacy data from the first cohort (≈25% of enrollment, 5 patients) in its Phase 2a UTOPIA‑1 trial of Trichomylin® softgel capsules for cancer‑related pain.
• Early signals show reductions in average daily pain, pain interference, pain severity, and opioid use, with no serious adverse events attributed to the study drug.
• The results support continuation of the trial and provide a basis for potential progression to later‑stage studies.

Key Details

• Trial Design: Single‑arm, proof‑of‑concept Phase 2a (UTOPIA‑1) evaluating Trichomylin® softgel capsules in patients with advanced cancer experiencing moderate to severe pain.
• Enrollment Status: First 25% of enrolled patients have completed treatment; data presented for the initial cohort of five patients.
• Efficacy Highlights:
• Reduction in average daily pain scores.
• Decrease in pain interference and overall pain severity ratings.
• Lower opioid dosing required for breakthrough pain episodes.
• Safety Findings:
• No serious adverse events related to Trichomylin® reported.
• Adverse reactions were mild, expected, and occurred mainly during dose titration—consistent with prior Phase 1 data (Z‑TRI‑10001 trial, NCT04867057).
• Management Commentary:
• Dr. Julie Stakiw (Chief Medical Officer) emphasized the milestone of early outcomes from the first cohort and validation of trial design.
• Brent Zettl (CEO) noted that while data are preliminary, they reinforce confidence in Trichomylin® as a non‑opioid alternative for cancer pain and justify continued clinical development.
• Forward‑Looking Statements: The release contains typical forward‑looking language regarding future enrollment, potential progression to later‑stage trials, regulatory approvals, and commercialization prospects.

Notable Quotes

“These results provide initial insight into the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules as the UTOPIA‑1 trial continues to generate the data needed to support the possible progression into later‑stage trials.” – Dr. Julie Stakiw, Chief Medical Officer

“While the data remains early, the signals we are seeing reinforce our belief that Trichomylin® softgel capsules have the potential to address cancer‑related pain through a non‑opioid alternative and support our continued efforts to generate robust clinical evidence.” – Brent Zettl, CEO & Director